WARF: P97017US

Long-Lasting Chimeric Botulinal Toxins


Eric Johnson, Michael Goodnough, Carl Malizio, Alan Scott, William Tepp

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a chimeric botulinum toxin with an increased duration of action.
OVERVIEWBotulinum toxin is used for the treatment of involuntary muscle movements, pain, spasticity and other neurologic disorders. However, each injection provides only temporary relief, necessitating periodic injections.
THE INVENTIONUW–Madison researchers have developed a chimeric toxin comprising a botulinal neurotoxin heavy chain and nonclostridial toxin chain. The chimeric toxin has a longer lasting effect, reducing side effects and frequency of treatment.
  • Treatment of neurological disorders
  • Chimeric toxin lasts longer, providing a durable therapy with fewer side effects.
  • Patients can be treated less frequently.
For More Information About the Inventors
Contact Information
For current licensing status, please contact Andy DeTienne at or 608-960-9857.
The WARF Advantage

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.